At a glance
ClinicalIndex Comparison Record- ✓Invasive epithelial breast cancer (ductal, medullary, lobular, papillary, mucinous, or tubular) ≤3cm (T1-T2cN0), no prior surgery or neoadjuvant endocrine/chemotherapy
- ✓Age ≥18 years and female
- ✓Tumor dimension ≤3cm on ultrasound
- ✓Unifocal tumor
- ✕Multi-centric disease
- ✕Prior radiation to involved breast
- ✕Tumor size >3cm
- ✕Pregnant or lactating
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
In Brief
A Phase 2 clinical trial evaluating Radiomics on MRI and microbubble CEUS Contrast Enhanced Ultrasound (CEUS) for Breast Cancer. Currently recruiting, targeting 53 participants across 1 site.
Detailed Summary
1\. Efficacy of PULSAR preoperative radiation 2. Evaluate potential of microbubble CEUS as an alternative to operative SLNBx 3. Evaluate potential of OA to evaluate treatment response of pre-operative radiation on the tumor
Study Details
Timeline
Interventions
Through extracting and analyzing a large number of features from medical imaging, radiomics has shown promising results in treatment outcome prediction for many diseases including breast cancer (45-50). UTSW physics group has developed several new radiomic approaches and radiomic features, such as a multi-objective radiomics model(51) and a new radiomic "Shell" feature(52). As an exploratory end point for this trial, the investigators will explore the application radiomics using pre-treatment MRI, treatment parameters and clinical characteristics as input to predict pathological response of radiation therapy (XRT) based on pathology report of surgical tissues and local recurrence.
Microbubble Contrast non-FDA approved for route of administration